JPMorgan analyst Anupam Rama raised the firm’s price target on Travere Therapeutics (TVTX) to $44 from $42 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target raised to $35 from $31 at Citi
- Travere Therapeutics: Strong Growth Potential and Strategic Advancements Justify Buy Rating
- Travere Therapeutics’ Earnings Call Reveals Growth and Challenges
- Travere Therapeutics price target raised to $30 from $24 at TD Cowen
- Travere Therapeutics Posts Strong 2024 Financial Results